Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.25 -2.7 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,065.00 GF Score: 78/100

Q4 2019 Alnylam Pharmaceuticals Inc Earnings Call Transcript

Feb 06, 2020 / 01:30PM GMT
Release Date Price: $121.96 (+0.30%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss fourth quarter and year-end 2019 financial results. There will be a question-and-answer session to follow. Please be advised that this call is being played at the company's request. I would now like to turn the call over to the company.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - VP of IR & Communications

Good morning. I'm Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, Chief Executive Officer; Barry Greene, President; Pushkal Garg, Chief Medical Officer; Jeff Poulton, Chief Financial Officer; and Yvonne Greenstreet, Chief Operating Officer. Akshay Vaishnaw, our President of R&D, is traveling today and unable to join us for today's call.

For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of our newly redesigned investor page of our website at alnylam.com

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot